about
Maternal group B Streptococcus-related stillbirth: a systematic reviewChlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trialMaternal death: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataPreterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data.Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials.Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancyInfluenza vaccination of pregnant women and protection of their infants.Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads.Increased risk for group B Streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004-2008(1).Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants.Bacterial and Respiratory Viral Interactions in the Etiology of Acute Otitis Media in HIV-infected and HIV-uninfected South African Children.Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumoniaInvasive Group B Streptococcal Disease in South Africa: Importance of Surveillance Methodology.Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine DevelopmentKinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their InfantsGroup B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.Evaluation of Trans-Vag broth, colistin-nalidixic agar, and CHROMagar StrepB for detection of group B Streptococcus in vaginal and rectal swabs from pregnant women in South AfricaInfluenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial.Bordetella pertussis Infection in South African HIV-Infected and HIV-Uninfected Mother-Infant Dyads: A Longitudinal Cohort StudyGuidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy.Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization: Secondary Analysis of a Randomized Clinical Trial.Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.Maternal HIV infection associated with reduced transplacental transfer of measles antibodies and increased susceptibility to disease.Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: Results from a randomized controlled trial.Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants.Lessons learnt from enrolment and follow up of pregnant women and their infants in clinical trials in South Africa, a low-middle income country.Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.Serotype-Specific Cell-Mediated Immunity Associated With Clearance of Homotypic Group B Streptococcus Rectovaginal Colonization in Pregnant Women.Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants.Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants.HIV-1 Is Associated With Lower Group B Streptococcus Capsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women.Polyomaviruses-associated respiratory infections in HIV-infected and HIV-uninfected children.Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children.Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
P50
Q28082060-9169CB20-1BDA-4E14-BD30-3C61F8954A7CQ28262067-4FC9EDA5-9EF2-46B9-BE23-AA55CE56F319Q30380075-0558B79B-E3A4-4B74-AB64-43B107FE3259Q31119651-37CBFC7A-EFC0-4FA0-AD11-24D249CB4F03Q31119656-761AD02C-D24E-4FFA-890A-8286C48E7082Q31136863-69F14194-DB8D-4825-9455-0A7D8917294DQ33737096-E8DC4DE3-473B-4F47-9DD4-47C2591153F1Q33825474-4AA29507-EFED-4195-BC47-5D2F9628F57AQ34436687-D43D6B1C-EB8C-4CF8-9F10-746A8D9E6618Q34704088-9D3751F3-3399-4328-8B89-4DDEE32D40F2Q35229614-3C415FF5-14FD-4993-971A-63F4059257A0Q35306303-19F2E94F-614E-4DC1-830A-8F11C2BB050BQ35718477-6E9D1851-A22D-422C-9FA0-95197A00877AQ35745680-62937BFE-4EA8-41FE-BC6B-82399AFB9288Q35982773-9CE86DD5-EE8D-4718-802E-BCB464D7B9C4Q36083608-D1F2178D-C81D-4704-A387-C6B9566F09EFQ36236399-271CDAAF-9D99-4B72-B187-5CEC2FB3A9A8Q36306940-9EDE758F-10C3-4F4C-B27B-17FB0AAE8440Q36809473-D3DA4E3A-9D04-4425-B6D6-A814ABACEA64Q37036271-DE2C8722-B53A-4908-A9CA-F3FE632FF2E8Q37107424-577B6ACA-5BDC-4299-B7EC-E4683C36AD8AQ37410304-ECC2809D-EB42-4C56-8A52-AEBFCE8DCF87Q37477687-7F965E3D-1AD7-4AB6-91E0-7461D32D9E81Q37606399-2924DBEB-B69B-4FE1-8B95-93ED8F6B378DQ38390492-E392A9C7-D528-4452-BCEB-45A2AB5F6DFBQ38829068-74C46C53-CAE1-4997-B331-399CC5E2CCB1Q40113019-2FEA31A1-9BAD-45ED-8357-DFBEB3845457Q40175446-DB346C98-1815-4472-A8E1-8048F286D4CDQ40335317-4C536082-B7A4-4AC3-A880-840244CC20D5Q40497350-9EDFBBBE-2C0B-499B-BCAB-7E6D3E48539CQ40689992-207FD4CE-018D-408A-A892-01E5437BE710Q40735187-C43EDAEF-F24C-4C78-A451-20B6A7F747FAQ40946918-D91363DE-989C-4E22-AE7F-A3740CC610CFQ41002917-2010E9CE-22A0-4B17-910D-14B131F98567Q41503558-F77540B7-8078-4570-9058-B47C01AE0CA4Q41622579-0DC22EB8-E8BB-43D7-9135-3CDDCF578B78Q42228329-D3F83EBB-DA96-471E-9009-74E8A73818BBQ43978300-EC840929-A479-4BE6-83F2-F5318EAFB95AQ44223713-57377341-9587-4BBE-8778-C6BEE5986AECQ44407634-624169E4-0D6B-49A6-9A2E-BA9798DBD1CB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clare L. Cutland
@ast
Clare L. Cutland
@en
Clare L. Cutland
@es
Clare L. Cutland
@nl
Clare L. Cutland
@sl
type
label
Clare L. Cutland
@ast
Clare L. Cutland
@en
Clare L. Cutland
@es
Clare L. Cutland
@nl
Clare L. Cutland
@sl
prefLabel
Clare L. Cutland
@ast
Clare L. Cutland
@en
Clare L. Cutland
@es
Clare L. Cutland
@nl
Clare L. Cutland
@sl
P106
P1153
9243286600
P21
P31
P496
0000-0001-8250-8307